title: Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma.
abstract: BACKGROUND
  Acute respiratory tract infections are common ailments to all individuals and the human rhinoviruses (HRVs) cause most of these infections. Pregnant women have increased susceptibility and disease severity to viral infections like influenza and HRVs, as do asthmatics. Successful pregnancy requires immunological modulation to permit fetal tolerance.
  
  
  OBJECTIVE
  To determine whether pregnant women have reduced innate antiviral interferon (IFN) responses to HRV infection compared with non-pregnant women.
  
  
  METHODS
  An in vitro culture system was used, where peripheral blood mononuclear cells (PBMCs) were isolated from whole blood of 54 women, including 10 stable asthmatics who were pregnant and 10 who were not pregnant, 10 non-asthmatic women who were pregnant, 10 who were ≥6 months post partum and 10 who were not pregnant. Samples were also collected from four exacerbating pregnant asthmatics. PBMCs were cultured with HRV43 and HRV1B. The antiviral proteins IFNα and IFNλ were measured from culture supernatants by ELISA.
  
  
  RESULTS
  Compared with healthy non-pregnant women, pregnant women had significantly reduced innate IFN responses to HRV infection (p<0.02), persisting ≥6 months post partum (p≤0.02). Pregnant asthmatics had significantly reduced IFNλ responses compared with healthy non-pregnant women (p≤0.034), while during current asthma exacerbations a decrease in IFNα (p≤0.023) and IFNλ (p=0.007) was observed. Induction by a TLR7 agonist induced a similar pattern of decreased innate IFNs during pregnancy as observed when HRV was the inducing agent.
  
  
  CONCLUSIONS
  Reduced antiviral IFNs during pregnancy and asthma provide an important mechanism for increased susceptibility, morbidity and mortality in pregnant women with respiratory viral infection.
authors.affiliation: Department of Respiratory Medicine, Centre for Asthma and Respiratory Disease, The University of Newcastle, School of Medicine and Public Health , New Lambton, NSW, Australia, 2350. rebecca.l.forbes@uon.edu.au
authors.forename: Rebecca Louise
authors.initials: RL
authors.lastname: Forbes
authors.forename: Peter G
authors.initials: PG
authors.lastname: Gibson
authors.forename: Vanessa E
authors.initials: VE
authors.lastname: Murphy
authors.forename: Peter A B
authors.initials: PA
authors.lastname: Wark
mesh_terms: D000328:Adult; D001249:Asthma / Q000276:immunology*; D002478:Cells, Cultured; D003430:Cross-Sectional Studies; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D007113:Immunity, Innate; D016898:Interferon-alpha / Q000096:biosynthesis; D007372:Interferons / Q000096:biosynthesis*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D010850:Picornaviridae Infections / Q000276:immunology*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology*; D011251:Pregnancy Complications, Infectious / Q000276:immunology; D012229:Rhinovirus; D051199:Toll-Like Receptor 7 / Q000276:immunology; D055815:Young Adult
chemical_list: D016898:Interferon-alpha; C495348:TLR7 protein, human; D051199:Toll-Like Receptor 7; D007372:Interferons